16 completed, 5 terminated, 4 recruiting. 25 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 16, Terminated 5, Recruiting 4 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperkalemia: new trials by email Literature Review of Hyperkalemia trials Research Report on Hyperkalemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia WS016 - Hyperkalemia | Phase 3 | Recruiting | Waterstone Pharmaceutical (Wuhan) Co., LTD. | 300 | 2026-09-25 | 2026-10-26 |
| Patiromer and Diet/hrQoL in Chronic Dialysis Patiromer 8400 MG [Veltassa], Placebo - Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4 | Phase 3 | Recruiting | Mario Negri Institute for Pharmacological Research | 40 | 2025-07-08 | 2025-09-04 |
| A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia WS016, Placebo - Hyperkalemia | Phase 3 | Recruiting | Waterstone Pharmaceutical (Wuhan) Co., LTD. | 420 | 2024-12-23 | 2025-11-26 |
| Patiromer Trial in CKD Stage IIIB to V Veltassa Oral Powder Product, Placebo - Hyperkalemia | Phase 3 | Terminated | Mario Negri Institute for Pharmacological Research | 2 | 2023-08-02 | 2024-11-12 |
| Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) - Hyperkalemia, Renal Insufficiency, Chronic | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 262 | 2022-02-10 | 2026-04-13 |
| Lokelma for RAAS Maximisation in CKD & Heart Failure. Lokelma Oral Product - Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction | Phase 3 | Completed | St George's, University of London | 112 | 2022-01-19 | 2026-04-27 |
| A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril - Renal Insufficiency, Chronic, Hyperkalemia | Phase 3 | Terminated | AstraZeneca | 1112 | 2021-09-30 | 2026-01-08 |
| A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes, Placebo - Hyperkalemia | Phase 3 | Completed | Zeria Pharmaceutical | 85 | 2021-08-03 | 2023-04-20 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. Sodium Zirconium Cyclosilicate 5g, Sodium Zirconium Cyclosilicate 10g, Placebo - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 270 | 2021-05-06 | 2025-05-14 |
| Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) Sodium Zirconium Cyclosilicate (SZC), SZC Placebo - Hyperkalemia | Phase 3 | Terminated | AstraZeneca | 2690 | 2021-04-30 | 2025-06-18 |
| Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Sodium zirconium cyclosilicate, Placebo - Hyperkalaemia, Metabolic Acidosis | Phase 3 | Terminated | AstraZeneca | 39 | 2021-03-22 | 2023-10-06 |
| Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects Sodium Zirconium Cyclosilicate, Placebo - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 134 | 2020-11-16 | 2023-03-28 |
| Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) Patiromer, Placebos - Hyperkalemia | Phase 3 | Completed | Vifor Pharma, Inc. | 1195 | 2019-04-24 | 2023-02-24 |
| An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2) - Hyperkalaemia | Phase 3 | Recruiting | AstraZeneca | 140 | 2019-04-02 | 2026-08-13 |
| A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. Placebo, Sodium Zirconium Cyclosilicate (ZS) - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 196 | 2017-12-14 | 2020-02-20 |
| Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia Zirconium Cyclosilicate - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 150 | 2017-09-04 | 2020-05-01 |
| ZS Ph2/3 Dose-response Study in Japan Sodium Zirconium Cyclosilicate (ZS) 5g, Sodium Zirconium Cyclosilicate (ZS) 10g, Placebo - Hyperkalemia | Phase 2 / Phase 3 | Completed | AstraZeneca | 103 | 2017-06-14 | 2019-05-20 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g, Placebo - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 267 | 2017-03-03 | 2020-08-19 |
| Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Sodium zirconium cyclosilicate - Sodium Zirconium Cyclosilicate, Hyperkalemia | Phase 3 | Completed | Guangdong Provincial People's Hospital | 62 | 2016-11-01 | 2022-05-19 |
| Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months Sodium Zirconium Cyclosilicate - Hyperkalemia | Phase 3 | Completed | ZS Pharma, Inc. | 751 | 2014-06-30 | 2018-06-27 |
Showing 20 of 25. Sign in to see all of them.
Renal Insufficiency, Chronic (8) · Acute Kidney Injury (2) · Acidosis (1) · Atrial Fibrillation (1) · Diabetes Mellitus, Type 2 (1) · Heart Failure (1) · Hyperparathyroidism, Secondary (1) · Hypertension (1) · Kidney Diseases (1) · Pseudohypoaldosteronism (1) · Tachycardia, Ventricular (1)
Metabolic Diseases (25) · Nutritional and Metabolic Diseases (25) · Water-Electrolyte Imbalance (25) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Renal Insufficiency (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Chronic Disease (8) · Disease Attributes (8) · Kidney Diseases (8) · Cardiovascular Diseases (2)
sodium zirconium cyclosilicate (14) · patiromer (3) · Lisinopril (2) · Streptozocin (2) · Suspensions (2) · zircon (2) · Calcium (1) · Irbesartan (1) · Losartan (1) · Valsartan (1)
AstraZeneca (10) · ZS Pharma, Inc. (4) · Mario Negri Institute for Pharmacological Research (2) · Waterstone Pharmaceutical (Wuhan) Co., LTD. (2) · Guangdong Provincial People's Hospital (1) · Relypsa, Inc. (1) · St George's, University of London (1) · US Department of Veterans Affairs (1) · Vifor Fresenius Medical Care Renal Pharma (1) · Vifor Pharma, Inc. (1) · Zeria Pharmaceutical (1)
United States (12) · China (8) · Japan (8) · Italy (6) · Russia (6) · United Kingdom (6) · Ukraine (5) · Australia (4) · Brazil (4) · Canada (4) · Germany (4) · India (4) · Poland (4) · Spain (4) · Argentina (3)
Henrik Rasmussen, MD, PhD (3) · Debasish Banerjee, MD FRCP (1) · Giuseppe Remuzzi, MD (1) · Glenn M. Chertow, MD, MPH (1) · Henrik Rasmussen, MD (1) · Julian Platon, MD, PhD (1) · Linda Fried, MD MPH (1) · Shuangxin Liu, Ph.D (1) · Steven Fishbane, MD (1) · Steven Fishbane, Professor, MD (1) · Yusuke Tomioka (1) · Zhaohui Ni (1)
PMID 32588430, PMID 31791288, PMID 24206457, PMID 24552328, PMID 25014549, PMID 25157242, PMID 25402495, PMID 25415807, PMID 29728199, PMID 30445841, PMID 32030422, PMID 32779057, PMID 33098526, PMID 33608263, PMID 35135481, PMID 35900838, PMID 37230521, PMID 37385905, PMID 38622759, PMID 38682786, PMID 39112102, PMID 39159624, PMID 39340493, PMID 39969301, PMID 40548378, PMID 40618849, PMID 41957746
2018 (2), 2023 (2), 2017 (1), 2025 (1)